N.I. Pirogov Russian National Research Medical University, Moscow; Morozov City Children's Clinical Hospital, Moscow

The favorable pharmacokinetic profile of an antiepilepttc drug with linear kinetics, stable blood concentration, and no clinical interaction with other agents is important in treating epilepsy in children and adolescents in the outpatient setting. Levetinol (levetiracetam) meets these requirements. Objective: to assess the use of Levetinol in outpatient neuropediatric practice. Sixty-one patients aged 2 to 17 years with different types of epilepsy were examined. Forty-seven children were observed to have concomitant (neurological, somatic, and endocrine) diseases, which required a particularly careful approach to choosing an antiepileptic drug. Levetinol was given in a therapeutic dose of 30 to 70 mg/kg/day. TVventy-three (37,7%) children were on monotherapy; 33 (54%) had duo therapy; 5 (8,1%) received 3 drugs. A positive clinical effect was achieved in 53 children - in most at 3 months of therapy: 25, 50, and 75% reductions in seizures in 2,11, and 3 patients, respectively; no seizures within 3-5 months in 38 (62,2%) patients. Levetinol (levetiracetam) demonstrated a high therapeutic efficacy and good tolerability in patients, including children with comorbidities, owing to which it has an advantage over other medicaments used in outpatient neuropediatric practice.